NYSE · Dividend

Bio-Rad Laboratories, Inc. (BIO.B) Dividend

$389.98 NYSE: BIO.B Market Cap $10.43B

Data as of Nov 17, 2026 close · Source: Financial Modeling Prep (methodology)

MetricValue
Dividend YieldNone
Indicated Annual Dividend—
Payout Ratio—
FCF Yield3.17%
Current Price$389.98

Dividend Analysis

Bio-Rad Laboratories, Inc. (BIO.B) does not currently pay a dividend, based on the latest available data. Companies that do not pay dividends may use earnings for reinvestment, acquisitions, share buybacks, or debt repayment instead.

Free cash flow yield of 3.17% covers the 0.00% dividend yield.

Dividend yield against peers

Bio-Rad Laboratories, Inc. has the lowest dividend yield of the 9 companies compared here.

CompanyYieldP/EPrice
Medtronic plc (MDT)3.02%23.33$102.32
Abbott Laboratories (ABT)2.43%38.41$104.71
Stryker Corporation (SYK)1.15%31.57$317.54
ResMed Inc. (RMD)1.15%20.92$237.85
Intuitive Surgical, Inc. (ISRG)0.00%54.04$430.53
Boston Scientific Corporation (BSX)0.00%18.42$43.03
Edwards Lifesciences Corporation (EW)0.00%59.08$105.43
DexCom, Inc. (DXCM)0.00%30.09$82.04
Bio-Rad Laboratories, Inc. (BIO.B)0.00%10.12$389.98

Bio-Rad Laboratories, Inc. (BIO.B) dividend — frequently asked questions

Does Bio-Rad Laboratories, Inc. (BIO.B) pay a dividend?

No, Bio-Rad Laboratories, Inc. (BIO.B) does not currently pay a dividend.

Dividend yields of other Medical - Devices stocks

ABT yield 2.43%MDT yield 3.02%SYK yield 1.15%RMD yield 1.15%PHG yield 3.29%ZBH yield 0.90%All Medical - Devices stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNYSE High ROE StocksAll stock screens
BIO.B Overview BIO.B Financials Screen Dividend Stocks

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.